Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 201–300 of 679
Williamson, D. J., Gogate, J. P., Sliwa, J. K. K., Manera, L. S., Preskorn, S. H., Winokur, A., Starr, H. L., & Daly, E. J. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14318 · Cited by 15
Self-citationBlinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
Hovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 16
Chiappini, S., Guirguis, A., Schifano, N., Corkery, J., Semeraro, F., Mosca, A., D’Andrea, G., Papanti, G. D., Arillotta, D., Floresta, G., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111213 · Cited by 15
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
Molero, P., Ibáñez, Á., de Diego-Adeliño, J., Ramos‐Quiroga, J. A., Dorado, M. G., Rengel, P. M. L., & Sáiz, P. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03149-z · Cited by 15
Katz, E. G., McNulty, P., Levitan, B. S., Treichler, P., Martynowicz, J., & Jamieson, C. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00340-6 · Cited by 15
Goswamee, P., Rice, R., Leggett, E., Zhang, F., Manicka, S., Porter, J. H., & McQuiston, A. R. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108965 · Cited by 15
Palhano-Fontes, F., Cavalcanti-Ribeiro, P., Gonçalves, K. T. D. C., de Almeida, V. R. N., Barbosa, D. C., Ferreira, M. A. D. A., Bolcont, R., Souza, L. C. A. M. D., dos Santos, N. C., Lopes, E. I. T. C., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.141 · Cited by 14
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Bobo, W. V., Riva‐Posse, P., Goes, F. S., & Parikh, S. V. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190048 · Cited by 14
Chen, B. K., Pen, G. L., Eckmier, A., Rubinstenn, G., Jay, T. M., & Denny, C. A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab007 · Cited by 14
Gonçalves, K. T. D. C., Tavares, V. D. D. O., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Arcoverde, E., SANTOS, R. G. D., Hallak, J. E. C., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01925-6 · Cited by 13
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 13
Pharmacology of ketamine and esketamine as rapid-acting antidepressants
Pavlidi, P., Megalokonomou, A., Sofron, A., Kokras, N., & Dalla, C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.050 · Cited by 13
Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Shoib, S., Kotra, M., Javed, S., Nguyen, V.-S., & Malathesh, B. C. (2022) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0099 · Cited by 13
Sant, L. C. D., Sarin, L. M., Lucchese, A. C., Magalhães, E. T. P., Tuena, M. A., Nakahira, C., Porto, J. A. D., Lacerda, A. L. T., & Mari, J. D. J. (2022) · Pharmaceuticals · doi:10.3390/ph16010031 · Cited by 13
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 13
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang, X., Qing, M.-J., Rao, Y.-H., & Guo, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09726-5 · Cited by 13
Denee, T., Ming, T., Waller, J., Bailey, T., Rajkovic-Hooley, O., Middleton-Dalby, C., Le, H. H., Zhang, Q., McCrone, P., & Taylor, D. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1857580 · Cited by 12
Research progress of non-monoamine antidepressants
Zhang, H., Wang, B., & Cao, X. (2021) · Stress and Brain · doi:10.26599/sab.2021.9060002 · Cited by 12
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD)
Olivier, B., & Olivier, J. D. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_3 · Cited by 13
Chepke, C., Shelton, R. C., Sanacora, G., Doherty, T., Tsytsik, P., & Parker, N. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae058 · Cited by 12
Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials
Nayak, S. M., & Zahid, Z. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368367 · Cited by 12
Włodarczyk, A., Dywel, A., & Cubała, W. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020173 · Cited by 12
Vendrell-Serres, J., Soto-Angona, Ó., Rodríguez‐Urrutia, A., Inzoli, B., González, A., & Ramos‐Quiroga, J. A. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1097 · Cited by 12
What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Hope, J., Copolov, D., Tiller, J. W. G., Galbally, M., Hopwood, M., Newton, R., & Keks, N. A. (2023) · Australasian Psychiatry · doi:10.1177/10398562231211171 · Cited by 12
Ketamine treatment for depression: A model of care
Bayes, A. J., Dong, V., Martin, D. M., Alonzo, A., Kabourakis, M., & Loo, C. K. A. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211039166 · Cited by 12
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d694 · Cited by 12
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 11
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Więdłocha, M., Marcinowicz, P., Komarnicki, J., Tobiaszewska, M., Dębowska, W., Dębowska, M. D., & Szulc, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1398859 · Cited by 11
Kim, J., Lee, S., Shin, C., Han, K., Cho, S. J., Hong, N., & Han, C. (2024) · Pharmaceuticals · doi:10.3390/ph17091143 · Cited by 11
Hussain, S., Gale, C. K., Sarma, S., Smith, J. P., Bayes, A. J., & Loo, C. K. A. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251333577 · Cited by 11
Turkoz, I., Lopena, O. J., Salvadore, G., Sanacora, G., Shelton, R. C., & Fu, D. (2022) · CNS Spectrums · doi:10.1017/s1092852922000931 · Cited by 11
Ouyang, Y., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000041495 · Cited by 10
“15–17]”
InfluentialDeng, B.-R., Wang, D., Xie, Z., Wang, Y., Huang, L., Jiang, M., & Shen, T. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02430-y · Cited by 10
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
Li, H., Xu, W.-J., Wang, Y., Xie, S., & Wang, H. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1476449 · Cited by 10
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A., Spijker, J., Schoevers, R. A., & Kamphuis, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251332831 · Cited by 10
Avanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03556-4 · Cited by 10
Raffone, F., Mazzoni, F., Ciechi, A. D., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B. M., Olivola, M., & Martiadis, V. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104983 · Cited by 10
Shamabadi, A., Ahmadzade, A., Aqamolaei, A., Mortazavi, S. H., Hasanzadeh, A., & Akhondzadeh, S. (2022) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v17i3.9733 · Cited by 11
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Rognoni, C., Falivena, C., Costa, F., & Armeni, P. (2023) · PharmacoEconomics · doi:10.1007/s40273-022-01220-z · Cited by 10
Zhang, J., Sun, R., Cai, Y., Peng, B., Yang, X., & Gao, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041172 · Cited by 10
Marek, G. J., & Salek, A. A. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264069 · Cited by 10
Young, A. H., Abdelghani, M., Juruena, M. F., Nikolova, V. L., & Nilforooshan, R. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388392 · Cited by 10
Gałuszko‐Węgielnik, M., Jakuszkowiak‐Wojten, K., Wiglusz, M. S., Cubała, W. J., & Pastuszak, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1214972 · Cited by 10
Ketamine in depression and electroconvulsive therapy
Rozet, I. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001039 · Cited by 10
Bremner, J. D., Williamson, D., & Vaccarino, V. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.050 · Cited by 9
Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review
Kerr‐Gaffney, J., Tröger, A., Caulfield, A., Ritter, P. S., Rucker, J., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251350267 · Cited by 9
Chen, C., Zhou, N., & Hou, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251339378 · Cited by 9
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d696 · Cited by 9
Oliveira-Maia, A. J., Rive, B., Morrens, J., Godinov, Y., Cabrieto, J., Perualila, N. J., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250987 · Cited by 9
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Menegatou, I.-M., Papakyriakopoulou, P., Rekkas, D. M., Dallas, P. P., & Valsami, G. N. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02351-4 · Cited by 9
Vázquez, G. H., Gutiérrez, G., Rosenblat, J. D., Schaffer, A., Swainson, J., Ganapathy, K., Ravindran, N., Lam, R. W. M., Do, A., Giacobbe, P., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060967 · Cited by 9
Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Legge, C. D., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70008 · Cited by 8
Sliwa, J. K., Naranjo, R. R., Turkoz, I., Petrillo, M. P., Cabrera, P., & Trivedi, M. H. (2024) · CNS Spectrums · doi:10.1017/s1092852924000105 · Cited by 8
Self-citationIntranasal Administration of a Polymeric Biodegradable Film to C57BL/6 Mice
Balafas, E., Papakyriakopoulou, P., Kostomitsopoulos, N. G., & Valsami, G. N. (2023) · Journal of the American Association for Laboratory Animal Science · doi:10.30802/aalas-jaalas-22-000091 · Cited by 8
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression
Jerath, A. U., Oldak, S. E., Soni, M., Zaydlin, M., Martin, S., Brown, K., Cara, V., & Coffey, B. J. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.29245.bjc · Cited by 8
Treatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 8
Esketamine for treatment-resistant depression
(2020) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000043 · Cited by 8
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000268 · Cited by 7
“All three short-term efficacy studies, including the two that did not show statistical significance on the primary endpoint [TRANSFORM-1 (Fedgchin et al ., 2019) and TRANSFORM-3 (Ochs-Ross et al ., 2020)] demonstrated between-group mean differences relative to the comparator (a new oral…”
Self-citationApproval of esketamine for treatment-resistant depression – Authors' reply
Naudet, F., & Cristea, I. A. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30040-7 · Cited by 7
Le, G. H., Wong, S., Johnson, D. E., Lu, A., Orsini, D. K., Chisamore, N., Luch, S. D. D., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.121081 · Cited by 7
Monn, A., Eicher, C., Rüesch, A., Kronenberg, G., Offenhammer, B., Adank, A., de Bardeci, M., Ip, C.-T., Scheerer, H., Schaekel, L., et al. (2025) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2025.112001 · Cited by 7
KETAMINE AS A NOVEL DRUG FOR DEPRESSION TREATMENT
Kaczmarek, B., Kowalski, K. E., Bogudzińska, B., & Piotrowski, P. (2021) · Psychiatria Danubina · doi:10.24869/psyd.2021.468 · Cited by 7
Balaram, K., van Dyck, L. I., Wilkins, K. M., & Maruca-Sullivan, P. E. (2023) · Current Geriatrics Reports · doi:10.1007/s13670-023-00389-1 · Cited by 7
Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory
Gammoh, O., & Bashatwah, R. M. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/13295 · Cited by 7
Treatment-resistant depression in children and adolescents
Chang, J.-C., Hai-Ti-Lin, Wang, Y.-C., & Gau, S. S. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.03.004 · Cited by 7
Liu, R., Liu, C., Feng, D., Guo, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414703 · Cited by 7
McAllister-Williams, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00001-3 · Cited by 7
AbdelWahab, M. A., Okasha, T. A., Shaheen, M. O., Nasr, M., Molokheya, T., Omar, A. E., Rabie, M. A., Mikhael, V. S., Hamed, H., & Ali, M. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.797150 · Cited by 7
Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N. J., Barbreau, S., & Mulhern-Haughey, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1250980 · Cited by 7
Borentain, S., Desai, P., Fu, D., Chen, L. N., Lane, R., Mathews, M., & Canuso, C. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221123046 · Cited by 7
Self-citationNaudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025) · BMC Medicine · doi:10.1186/s12916-025-04435-x · Cited by 6
“Among these, six were initiation studies (1 with a 1-week duration [40], five with a 4-week duration [9–11, 41, 42] and one was a continuation study [12].”
InfluentialSpravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
Raza, A. A., Ahmed, G., Zafar, H., Akhtar, S. O., Mobin, M. B., & Samadi, A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s548944 · Cited by 6
Silberbauer, L., Eggerstorfer, B., Michenthaler, P., Reichel, S., Stimpfl, T., Vanicek, T., Naderi‐Heiden, A., Kasper, S. F., Lanzenberger, R. R., & Gryglewski, G. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120466 · Cited by 7
Tatlı, S. Z., & Atagün, M. İ. (2025) · Actas Españolas de Psiquiatría · doi:10.62641/aep.v53i6.1946 · Cited by 7
Zhan, Z., Wang, X., Chen, Q., Xiao, Z., & Zhang, B. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043457 · Cited by 6
Caldieraro, M. A., Tung, T. C., Baena, L. M. A., Vilapriño, M., Corral, R. M., de la Serna, L. D. A., Uribe, E. S., KANEVSKY, G. A., & Cabrera, P. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.06.002 · Cited by 6
Ramezani, F., Mardani, P., Nemati, F., Cattarinussi, G., Sambataro, F., Schiena, G., Brambilla, P., & Delvecchio, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.118 · Cited by 6
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
Self-citationKetamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 6
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v33i3.13224 · Cited by 7
Clinical use of ketamine in psychiatric disorders
Dehestani, S., Mohammadpour, A. H., Sadjadi, S. A., Sathyapalan, T., & Sahebkar, A. (2022) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2022.05.008 · Cited by 6
Conformational flexibility within the small domain of human serine racemase
Koulouris, C. R., Bax, B. D., Atack, J. R., & Roe, S. M. (2020) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x20001193 · Cited by 6
Esketamine clinical trials: reply to Maju et al.
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602000027x · Cited by 6
New Somatic Treatments for Child and Adolescent Depression
Cullen, K. R., Padilla, L. E., Papke, V. N., & Klimes-Dougan, B. (2019) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-019-00194-8 · Cited by 5
Tavares, V. D. D. O., Gonçalves, K. T. D. C., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Nunes, E. A., Sarris, J. J., Perkins, D., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001946 · Cited by 5
Esketamine use in real-world clinical practice in patients with treatment-resistant depression
Conejero, I., Álvarez-García, R., Porras‐Segovia, A., de Granda-Beltrán, A. M., López, S. B., Stasio, E. D., Albarracín-García, L., López‐Castromán, J., Courtet, P., Baca‐García, E., et al. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2025.10096 · Cited by 5
Massaneda‐Tuneu, C., Martin, D. M., Glozier, N., Bayes, A. J., Cao, T. V., Thornton, N. L. R., Brettell, L., Antoniou, S., Barreiros, A. R., Flynn, M., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120192 · Cited by 5
Horato, N., Dalvi-Garcia, F., Dutra, P. E. P., & Nardi, A. E. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002122 · Cited by 5
Huc, M., Siddiqi, S., Myers, M., Colman, I., Salmaso, N., Jaworska, N., & Aguilar‐Valles, A. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03493-8 · Cited by 5
Ahmed, N. N., Albishi, F., Khan, S. A., Alsayegh, A., Stip, É., & Makhoul, S. (2023) · Middle East Current Psychiatry · doi:10.1186/s43045-023-00369-3 · Cited by 5
Quantitative evaluation of multiple treatment regimens for treatment-resistant depression
Feng, Y., Lv, Y., Yang, J., Xu, L., Chen, J., Huang, J., Ren, J., Zheng, Q., & Li, L. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf007 · Cited by 5
Zhang, Y., Song, Z., Zhang, H., Lin, H., Xu, P., Li, Z., He, Q., & Wei, B. (2025) · Biomedicines · doi:10.3390/biomedicines13051081 · Cited by 6
Kurosawa, K., Shibuya, M., Shimizu, H., & Pérez‐Ruixo, C. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1214 · Cited by 5
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.